Investigational drug · Phase 2
ARCT-2304
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza, Human.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "ARCT-2304"
First trial start
2024
Dec 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARCT-2304", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza, Human
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ARCT-2304" as an intervention, largest first.
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsPivotal-lookingCompleted
Arcturus Therapeutics, Inc.Industry
NCT06602531 · 212 participants · Start Dec 10, 2024 · Primary completion Jun 13, 2025
Drug: ARCT-2304; Control vaccine younger adults and 1 more · For: Influenza, Human
Sites: La Mesa, California; San Bernardino, California; Longmont, Colorado · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Extended dosing intervals enhance the durability of a self-amplifying mRNA vaccine against pandemic H5N1 influenza: a randomized, observer-blind, dose-finding Phase I study.
Pragalos AA, Pacciarini F, Jin H, et al. · Nat Commun 2026
Also in development for Influenza, Human
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- Flu mRNAGSK6479720A, GSK6498032APhase 22 trials
GSK · Influenza, Human
- DL001ZF2G22B, F2H23HPhase 21 trial
GSK · Influenza, Human
- DL001Z-NHF2H23D, F2H23BPhase 21 trial
GSK · Influenza, Human
- GSK5800544APhase 21 trial
GSK · Influenza, Human
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.